当前位置: X-MOL 学术Annu. Rev. Biomed. Eng. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Targeted and Nontargeted α-Particle Therapies.
Annual Review of Biomedical Engineering ( IF 12.8 ) Pub Date : 2018-06-04 00:00:00 , DOI: 10.1146/annurev-bioeng-062117-120931
Michael R McDevitt 1, 2 , George Sgouros 3 , Stavroula Sofou 4
Affiliation  

α-Particle irradiation of cancerous tissue is increasingly recognized as a potent therapeutic option. We briefly review the physics, radiobiology, and dosimetry of α-particle emitters, as well as the distinguishing features that make them unique for radiopharmaceutical therapy. We also review the emerging clinical role of α-particle therapy in managing cancer and recent studies on in vitro and preclinical α-particle therapy delivered by antibodies, other small molecules, and nanometer-sized particles. In addition to their unique radiopharmaceutical characteristics, the increased availability and improved radiochemistry of α-particle radionuclides have contributed to the growing recent interest in α-particle radiotherapy. Targeted therapy strategies have presented novel possibilities for the use of α-particles in the treatment of cancer. Clinical experience has already demonstrated the safe and effective use of α-particle emitters as potent tumor-selective drugs for the treatment of leukemia and metastatic disease.

中文翻译:



靶向和非靶向 α 粒子疗法。



癌组织的 α 粒子照射越来越被认为是一种有效的治疗选择。我们简要回顾了 α 粒子发射器的物理学、放射生物学和剂量测定,以及使其在放射性药物治疗中独一无二的显着特征。我们还回顾了 α 粒子疗法在癌症治疗中的新兴临床作用,以及最近对抗体、其他小分子和纳米尺寸粒子提供的体外和临床前 α 粒子疗法的研究。除了其独特的放射性药物特性外,α 粒子放射性核素的可用性增加和放射化学的改进也促使人们最近对 α 粒子放射治疗的兴趣日益浓厚。靶向治疗策略为使用 α 粒子治疗癌症提供了新的可能性。临床经验已经证明α粒子发射体可以安全有效地用作治疗白血病和转移性疾病的有效肿瘤选择性药物。

更新日期:2018-06-04
down
wechat
bug